Neonatal community-acquired pneumonia: Pathogens and treatment

被引:10
|
作者
Wang, Hua [1 ]
Tang, Jun [1 ]
Xiong, Ying [1 ]
Li, Xihong [1 ]
Gonzalez, Fernando [2 ]
Mu, Dezhi [1 ,2 ]
机构
[1] Sichuan Univ, W China Univ Hosp 2, Dept Pediat, Chengdu 610041, Peoples R China
[2] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA
关键词
community-acquired pneumonia; drug sensitivity; neonate; pathogen; INFECTIONS; ETIOLOGY; DIAGNOSIS; CHILDREN; AGENTS; RATES;
D O I
10.1111/j.1440-1754.2010.01814.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aim: To analyse the bacterial pathogens and drug sensitivities for neonatal community-acquired pneumonia. Methods: Seven hundred sixty sputum samples from newborns with community-acquired pneumonia were cultured to determine microbial organisms present and their drug sensitivities. Results: Of the 760 specimens, 425 grew pathogens for a 55.9% positive rate. Among the 425 positive cultures, 278 grew gram-negative organisms (65.4%), 142 grew gram-positive organisms (33.3%), while 5 grew fungus (1.3%). The most common gram-negative organisms were Escherichia coli, Klebsiella pneumoniae and Hemophilus influenzae, while the most common gram-positive organisms were Staphylococcus aureus, Staphylococcus epidermidis and Staphylococcus haemolyticus. To the gram-negative organisms, the most sensitive drugs were meropenem, imipenem and amikacin, while to the gram-positive ones were vancomycin, teicoplanin and quinupristin/dalfopristin. Conclusions: The most common causative bacteria were gram-negative organisms, which were highly sensitive to Meropenem, Imipenem and Amikacin, yet often treatable with more focused antibiotic coverage, which depended on the bacterium identified.
引用
收藏
页码:668 / 672
页数:5
相关论文
共 50 条
  • [21] Tigecycline in the Treatment of Community-Acquired Pneumonia
    Curcio, Daniel
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1275 - 1289
  • [22] Levofloxacin in the treatment of community-acquired pneumonia
    Noreddin, Ayman M.
    Elkhatib, Walid F.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2010, 8 (05) : 505 - 514
  • [23] Changes in pathogens and pneumococcal serotypes causing community-acquired pneumonia in The Netherlands
    Vestjens, Stefan M. T.
    Wagenvoort, Gertjan H. J.
    Grutters, Jan C.
    Meek, Bob
    Aldenkamp, Arnoud F.
    Vlaminckx, Bart J. M.
    Bos, Willem-Jan W.
    Rijkers, Ger T.
    van de Garde, Ewoudt M. W.
    VACCINE, 2017, 35 (33) : 4112 - 4118
  • [24] Measuring the incidence of adult community-acquired pneumonia in a Native American community
    Watt, J. P.
    Moisi, J. C.
    Donaldson, R. L. A.
    Reid, R.
    Ferro, S.
    Whitney, C. G.
    Santosham, M.
    O'Brien, K. L.
    EPIDEMIOLOGY AND INFECTION, 2010, 138 (08) : 1146 - 1154
  • [25] Current treatment of community-acquired pneumonia
    Liapikou, Adamantia
    Torres, Antonio
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (10) : 1319 - 1332
  • [26] Etiology and treatment of community-acquired pneumonia in ambulatory children
    Wubbel, L
    Muniz, L
    Ahmed, A
    Trujillo, M
    Carubelli, C
    Mccoig, C
    Abramo, T
    Leinonen, M
    Mccracken, GH
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (02) : 98 - 104
  • [27] Management of community-acquired pneumonia
    Ehsan, Mohsin
    Metersky, Mark L.
    CURRENT PULMONOLOGY REPORTS, 2013, 2 (04) : 218 - 225
  • [28] Genetics in community-acquired pneumonia
    Rijkers, Ger T.
    Holzer, Lara
    Dusselier, Tiara
    CURRENT OPINION IN PULMONARY MEDICINE, 2019, 25 (03) : 323 - 329
  • [29] Community-acquired Pneumonia in Childhood
    Hansen, G.
    Wetzke, M.
    Baumann, U.
    Schwerk, N.
    Seidenberg, J.
    MONATSSCHRIFT KINDERHEILKUNDE, 2018, 166 (01) : 16 - 23
  • [30] Childhood community-acquired pneumonia
    Meyer Sauteur, Patrick M.
    EUROPEAN JOURNAL OF PEDIATRICS, 2024, 183 (03) : 1129 - 1136